Assessment of High Risk for Alzheimer’s Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan: A Preliminary Study

BACKGROUND: In Alzheimer’s disease (AD), cognitive impairment begins 10–15 years later than neurodegeneration in the brain. Plasma biomarkers are promising candidates for assessing neurodegeneration in people with normal cognition. It has been reported that subjects with the concentration of plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chaur-Jong, Chiu, Ming-Jang, Pai, Ming-Chyi, Yan, Sui-Hing, Wang, Pei-Ning, Chiu, Pai-Yi, Lin, Chin-Hsien, Chen, Ta-Fu, Yang, Fu-Chi, Huang, Kuo-Lun, Hsu, Yi-Ting, Hou, Yi-Chou, Lin, Wei-Che, Lu, Cheng-Hsien, Huang, Li-Kai, Yang, Shieh-Yueh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609520/
https://www.ncbi.nlm.nih.gov/pubmed/34870102
http://dx.doi.org/10.3233/ADR-210310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609520/
https://www.ncbi.nlm.nih.gov/pubmed/34870102
http://dx.doi.org/10.3233/ADR-210310

Ejemplares similares